Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generon (Shanghai) Corporation has announced the commencement of the Phase II clinical trial of F-627 in women with breast cancer receiving myelotoxic chemotherapy.
Subscribe to our email newsletter
The company has received FDA regulatory clearance for the randomized, multicenter, open-label, active-controlled trial of F-627.
Generon CEO Yu-Liang Huang said, "This is the first innovative biologic drug developed by a Chinese biotech company entering global clinical development."
The trial is expected to enroll 200 patients and to be conducted at 35 clinical centers in North America and Europec.
The primary objective of this study is to analyze the efficacy and safety of various once-per-cycle dosing of F-627 as compared with the standard dosing of Neulasta (pegfilgrastim) in breast cancer patients undergoing myelotoxic chemotherapy.